ArticleCureus2026
Association of Finerenone Dose and Estimated Glomerular Filtration Rate (eGFR) Slope Changes in Patients With Diabetic Kidney Disease: A Real-World Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Finerenone demonstrates renoprotective effects in clinical trials; however, real-world evidence regarding the association between maintenance doses (10 mg vs. 20 mg) and estimated glomerular filtration rate (eGFR) slope changes remains scarce. We investigated the real-world impact of finerenone dosage and baseline clinical factors on eGFR slope trajectory in patients with diabetic kidney disease (DKD). Methods We retrospectively analyzed 104 patients with DKD who initiated finerenone and completed at least six months of follow-up. The primary outcome was the change in annual eGFR slope from the one-year pre-initiation period to the six-month post-initiation period. Secondary outcomes included changes in urinary albumin-to-creatinine ratio (UACR), urinary protein-to-creatinine ratio (UPCR), serum potassium, and blood pressure. Multivariable linear regression analysis was conducted to identify independent baseline factors associated with eGFR slope improvement. Results Following finerenone initiation, the overall eGFR slope improved from -5.20 to +0.27 mL/min/1.73 m²/year (p = 0.0144). Among subgroup analyses, significant slope improvement was observed in patients maintained on the 10 mg/day dose (n = 52, from -7.11 to +3.35 mL/min/1.73 m²/year, p = 0.00041), whereas the 20 mg/day group (n = 52) remained in a stable trajectory (-3.29 to -2.85 mL/min/1.73 m²/year, p = 0.865). In multivariable analysis, concomitant sodium-glucose cotransporter 2 (SGLT2) inhibitor use (B = +9.79, p = 0.016), younger age, lower baseline eGFR, and lower body mass index were independently associated with slope improvement. UACR decreased significantly (p = 0.0098), while serum potassium increased modestly (+0.086 mmol/L, p = 0.045) without clinically meaningful blood pressure changes. Conclusions Finerenone significantly attenuated eGFR decline in real-world patients with DKD, with slope improvement observed in patients maintained on the 10 mg/day dose. Concomitant SGLT2 inhibitor use was independently associated with greater improvement in eGFR slope, supporting the clinical utility and practical dose management of finerenone in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.